Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy.

Mengwu Pan Valeria Solozobova Nane C Kuznik Nicole Jung Simone Gräßle Victor Gourain Yvonne M Heneka Christina A Cramer von Clausbruch Oliver Fuhr Ravi S N Munuganti Danilo Maddalo Christine Blattner Antje J Neeb Adam Sharp Laura Cato Carsten Weiss Rinath M Jeselsohn Veronique Orian-Rousseau Stefan Bräse Andrew C B Cato

Published in: Cancer research communications (2023)

breast cancer therapeutics. This compound also activates wild-type p53 and disrupts the gain-of-function tumorigenic activity of mutant p53, resulting in cell-cycle arrest and the induction of apoptosis.

Keyphrases

cell cycle arrest
wild type
estrogen receptor
cancer therapy
cell death
pi k akt
drug delivery
small molecule
oxidative stress